1
|
Moerdler S, DuVall AS, Hayes-Lattin B, Grimes A, Prasad PK, Molina JC, Monga V, Freyer DR, Roth ME. Gaps in Adolescent and Young Adult Cancer Education in Oncology Fellowship Training. J Adolesc Young Adult Oncol 2024; 13:97-104. [PMID: 37477884 DOI: 10.1089/jayao.2023.0056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023] Open
Abstract
Purpose: Adolescents and young adults (AYAs, 15-39 years) with cancer experience disparities in care and outcomes compared with older/younger patients. AYAs receive care from medical and pediatric oncologists, however, little is known about the extent of training fellows receive. This needs assessment evaluating current AYA oncology (AYA-O) education in pediatric and medical oncology fellowship programs to identify knowledge gaps for curricular development. Methods: An anonymous, cross-sectional, web-based survey developed by pediatric and medical oncologists was sent to medical (n = 178) and pediatric (n = 119) hematology/oncology program directors (PDs) at 251 sites in the United States. PDs were asked to participate and distribute the survey to their fellows. Survey questions addressed current AYA curriculum, provider comfort, and priorities for future AYA educational content. Results: Participants from 69/251 programs responded (program response rate = 27%), including 51 PDs (32 pediatric, 19 medical oncology) and 58 fellows (33 pediatric, 25 medical oncology). Eighty-five percent of PDs (44/51) reported lacking formal AYA curricula. Of these, 80% (35/44) offer some topic-specific lectures, while 20% (9/44) provide little/no education for any topics. For nearly all topics, at least 45% of combined respondents reported little/no education. Respondents believe AYA topics are important for inclusion in future curricula. The most important topics for inclusion reported were oncofertility (82%), survivorship (78%), and communication (77%). Conclusions: There are large and actionable gaps in AYA-O education during fellowship training. Efforts are underway to develop AYA-O curriculum to provide both medical and pediatric oncology fellows with the knowledge and skills required to provide optimal AYA care.
Collapse
Affiliation(s)
- Scott Moerdler
- Division of Pediatric Hematology Oncology, Department of Pediatrics, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Adam S DuVall
- Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
| | - Brandon Hayes-Lattin
- Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
| | - Allison Grimes
- Department of Pediatrics, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA
| | - Pinki K Prasad
- Hematology and Oncology Section, Department of Pediatrics, Louisiana State University Health, Children's Hospital of New Orleans, New Orleans, Louisiana, USA
| | - John C Molina
- Department of Hematology Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Varun Monga
- Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA
| | - David R Freyer
- Department of Pediatrics and Population and Public Health Sciences, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA
- USC Norris Comprehensive Cancer Center, Los Angeles, California, USA
| | - Michael E Roth
- Department of Pediatrics Patient Care, Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
2
|
Prasad PK, Mahajan P, Hawkins DS, Mostoufi-Moab S, Venkatramani R. Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist. Pediatr Blood Cancer 2020; 67:e28141. [PMID: 32275118 DOI: 10.1002/pbc.28141] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 11/11/2019] [Accepted: 12/09/2019] [Indexed: 02/03/2023]
Abstract
Differentiated thyroid cancer (DTC) is the most common childhood thyroid malignancy. The standard of care for pediatric DTC is total thyroidectomy followed by radioactive iodine (RAI) treatment when indicated. Molecular changes and potential therapeutic targets have been recently described in pediatric thyroid cancer. Pediatric oncologists are increasingly involved in the evaluation of thyroid nodules in childhood cancer survivors and in the management of advanced thyroid cancer. In 2015, the American Thyroid Association published management guidelines for children with DTC. We provide an overview of the current standard of care and highlight available targeted therapies for progressive or RAI refractory DTC.
Collapse
Affiliation(s)
- Pinki K Prasad
- Louisiana State University Health Sciences Center, Children's Hospital of New Orleans, New Orleans, Louisiana
| | - Priya Mahajan
- Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Douglas S Hawkins
- Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
| | - Sogol Mostoufi-Moab
- Divisions of Endocrinology and Hematology/Oncology, Department of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Rajkumar Venkatramani
- Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
3
|
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, Am Zehnhoff-Dinnesen A, Cohn RJ, Landier W. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 2019; 20:e29-e41. [PMID: 30614474 PMCID: PMC7549756 DOI: 10.1016/s1470-2045(18)30858-1] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 11/06/2018] [Accepted: 11/07/2018] [Indexed: 01/26/2023]
Abstract
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
Collapse
Affiliation(s)
- Eva Clemens
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | | | - Renée L Mulder
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Leontien C M Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Melissa M Hudson
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Roderick Skinner
- Department of Pediatric and Adolescent Hematology/Oncology and Children's Hematopoietic Stem Cell Transplant Unit, Great North Children's Hospital and Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - Louis S Constine
- Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York, NY, USA
| | - Johnnie K Bass
- Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Claudia E Kuehni
- Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Pediatrics, Children's University Hospital of Bern, University of Bern, Bern, Switzerland
| | - Thorsten Langer
- Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany
| | - Elvira C van Dalen
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Edith Bardi
- Department of Pediatrics and Adolescent Medicine, Kepler Universitätsklinikum, Linz, Austria
| | | | - Penelope R Brock
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Beth Brooks
- Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA; Audiology and Speech Pathology Department, British Columbia's Children's Hospital, Vancouver, BC, Canada; School of Audiology and Speech Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Bruce Carleton
- Pharmaceutical Outcomes Programme, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Eric Caron
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Kay W Chang
- Department of Otolaryngology, Stanford University, Palo Alto, CA, USA
| | - Karen Johnston
- Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia
| | - Kristin Knight
- Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA
| | - Paul C Nathan
- Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Etan Orgel
- Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Pinki K Prasad
- Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of New Orleans, New Orleans, LA, USA
| | - Jan Rottenberg
- Department of Otolaryngology and Head and Neck Surgery, St Ann's University Hospital Brno, Masaryk University, Brno, Czech Republic
| | - Katrin Scheinemann
- Division of Pediatric Hematology/Oncology, Hospital for Children and Adolescents, Cantonal Hospital Aarau, Aarau, Switzerland; Division of Pediatric Hematology/Oncology, University for Children's Hospital Basel, Basel, Switzerland; Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada
| | - Andrica C H de Vries
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | - Thomas Walwyn
- Department of Pediatric and Adolescent Oncology, Perth Children's Hospital, Nedlands, WA, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia
| | - Annette Weiss
- Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
| | - Antoinette Am Zehnhoff-Dinnesen
- Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University of Münster, Münster, Germany
| | - Richard J Cohn
- Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia; School of Women's and Children's Health, University of New South Wales Medicine, Sydney, NSW, Australia
| | - Wendy Landier
- Institute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, AL, USA.
| |
Collapse
|
4
|
Brinkman TM, Li C, Vannatta K, Marchak JG, Lai JS, Prasad PK, Kimberg C, Vuotto S, Di C, Srivastava D, Robison LL, Armstrong GT, Krull KR. Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2016; 34:3417-25. [PMID: 27432919 DOI: 10.1200/jco.2016.66.4789] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE In the general population, psychological symptoms frequently co-occur; however, profiles of symptom comorbidities have not been examined among adolescent survivors of childhood cancer. PATIENTS AND METHODS Parents of 3,893 5-year survivors of childhood cancer who were treated between 1970 and 1999 and who were assessed in adolescence (age 12 to 17 years) completed the Behavior Problems Index. Age- and sex-standardized z scores were calculated for symptom domains by using the Childhood Cancer Survivor Study sibling cohort. Latent profile analysis identified profiles of comorbid symptoms, and multivariable multinomial logistic regression modeling examined associations between cancer treatment exposures and physical late effects and identified symptom profiles. Odds ratios (ORs) and 95% CIs for latent class membership were estimated and analyses were stratified by cranial radiation therapy (CRT; CRT or no CRT). RESULTS Four symptoms profiles were identified: no significant symptoms (CRT, 63%; no CRT, 70%); elevated anxiety and/or depression, social withdrawal, and attention problems (internalizing; CRT, 31%; no CRT, 16%); elevated headstrong behavior and attention problems (externalizing; CRT, no observed; no CRT, 9%); and elevated internalizing and externalizing symptoms (global symptoms; CRT, 6%; no CRT, 5%). Treatment with ≥ 30 Gy CRT conferred greater risk of internalizing (OR, 1.7; 95% CI, 1.0 to 2.8) and global symptoms (OR, 3.2; 95% CI, 1.2 to 8.4). Among the no CRT group, corticosteroid treatment was associated with externalizing symptoms (OR, 1.9; 95% CI, 1.2 to 2.8) and ≥ 4.3 g/m(2) intravenous methotrexate exposure was associated with global symptoms (OR, 1.5; 95% CI, 0.9 to 2.4). Treatment late effects, including obesity, cancer-related pain, and sensory impairments, were significantly associated with increased risk of comorbid symptoms. CONCLUSION Behavioral, emotional, and social symptoms frequently co-occur in adolescent survivors of childhood cancer and are associated with treatment exposures and physical late effects. Assessment and consideration of symptom profiles are essential for directing appropriate mental health treatment for adolescent survivors.
Collapse
Affiliation(s)
- Tara M Brinkman
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA.
| | - Chenghong Li
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kathryn Vannatta
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Jordan G Marchak
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Jin-Shei Lai
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Pinki K Prasad
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Cara Kimberg
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Stefanie Vuotto
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Chongzhi Di
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Deokumar Srivastava
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Leslie L Robison
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Gregory T Armstrong
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kevin R Krull
- Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
5
|
Wu XC, Prasad PK, Landry I, Harlan LC, Parsons HM, Lynch CF, Smith AW, Hamilton AS, Keegan THM. Impact of the AYA HOPE Comorbidity Index on Assessing Health Care Service Needs and Health Status among Adolescents and Young Adults with Cancer. Cancer Epidemiol Biomarkers Prev 2015; 24:1844-9. [PMID: 26420768 PMCID: PMC4670595 DOI: 10.1158/1055-9965.epi-15-0401] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 09/22/2015] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Existing comorbidity indices were not developed for adolescent and young adults (AYA) 15 to 39 years of age. The aim of this study was to assess impact of comorbidities on health care service needs and health status among AYA cancer survivors using the newly developed AYA HOPE comorbidity index in comparison with the existing indices. METHODS Data on comorbid conditions were obtained from medical records and service needs and health status were from a survey of AYA cancer survivors. Prevalence of comorbidities was based on the AYA HOPE index. Charlson and NCI indices were compared. Multivariable logistic regression was used. RESULTS Of the 485 patients, 14.6% had ≥2 comorbidities based on the AYA HOPE Index. Prevalence of mental illness and obesity/overweight, which were not included in existing indices, were 8.2% and 5.8%, respectively. Prevalence of cardiovascular, endocrine, gastrointestinal, and neurologic conditions were higher with the AYA HOPE Index than the other two indices. Forty percent of AYA patients reported service needs, particularly for mental health services (25.2%) and support groups (17.7%). Having ≥2 comorbidities on the AYA index was associated with higher mental health service needs [OR, 2.05; 95% confidence interval (CI), 1.10-3.82] adjusting for demographic and clinical factors. Comorbidities were associated with fair/poor self-reported health status. CONCLUSION The AYA HOPE Index is a more comprehensive comorbidity index for AYA cancer patients than existing indices, and the number of comorbidities is associated with service needs and health status. IMPACT The AYA HOPE index could identify patients' additional service needs early in therapy.
Collapse
Affiliation(s)
- Xiao-Cheng Wu
- Department of Epidemiology, LSUHSC, New Orleans, Louisiana.
| | - Pinki K Prasad
- Department of Pediatric Hematology/Oncology, LSUSHC/Children's Hospital of New Orleans, New Orleans, Louisiana
| | - Ian Landry
- Department of Epidemiology, LSUHSC, New Orleans, Louisiana
| | - Linda C Harlan
- Applied Research Program, National Cancer Institute, Bethesda, Maryland
| | - Helen M Parsons
- University of Texas Health Science Center, San Antonio, Texas
| | - Charles F Lynch
- Department of Epidemiology, University of Iowa, Iowa City, Iowa
| | - Ashley W Smith
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Ann S Hamilton
- Preventive Medicine, University of Southern California Norris Cancer Center, Los Angeles, California
| | - Theresa H M Keegan
- Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, California
| |
Collapse
|
6
|
Shnorhavorian M, Harlan LC, Smith AW, Keegan THM, Lynch CF, Prasad PK, Cress RD, Wu XC, Hamilton AS, Parsons HM, Keel G, Charlesworth SE, Schwartz SM. Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: A population-based study. Cancer 2015. [PMID: 26214755 DOI: 10.1002/cncr.29328] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The fertility of adolescent and young adult (AYA) patients with cancer can be threatened by treatments, but to the authors' knowledge little is known regarding the extent to which providers discuss this with patients or recommend fertility preservation, or the patient and physician characteristics associated with these interactions. METHODS Questionnaires from 459 AYA patients with cancer who were diagnosed between 2007 and 2008 and recruited through 7 US population-based cancer registries were analyzed using sex-specific multivariable models. The authors assessed characteristics associated with not discussing therapy effects on fertility or fertility preservation options, and not making fertility preservation arrangements. RESULTS Males without a medical oncologist were more likely not to be told that therapy might affect fertility than those with a medical oncologist (male odds ratio [OR], 2.28; 95% confidence interval [95% CI], 1.03-5.00). Individuals without insurance (male OR, 2.91 [95% CI, 1.41-5.91] and female OR, 5.46 [95% CI, 1.59-18.72]); those raising children aged <18 years; and, among males only, those who received treatment posing no or a low fertility risk (OR, 3.39; 95% CI, 1.60-7.16) were more likely not to discuss fertility preservation with providers. Finally, among males, those without a college degree (OR, 1.98; 95% CI, 1.00-3.97), lacking private insurance (OR, 2.97; 95% CI, 1.16-7.63), and raising children aged <18 years (OR, 3.53; 95% CI, 1.63-7.65) were more likely to not make fertility preservation arrangements; too few females had made fertility preservation arrangements for similar analyses to be performed. CONCLUSIONS Discussion and action surrounding fertility preservation for AYA patients with cancer are associated with medical factors, patient socioeconomic data, and child-rearing status. These results highlight the need for insurance coverage for fertility preservation and increased awareness of fertility preservation options.
Collapse
Affiliation(s)
- Margarett Shnorhavorian
- Division of Pediatric Urology, Department of Urology, University of Washington, Seattle Children's Hospital, Seattle, Washington
| | - Linda C Harlan
- Applied Research Program, National Cancer Institute, Bethesda, Maryland
| | | | - Theresa H M Keegan
- Cancer Prevention Institute of California, Fremont, California.,Department of Health Research and Policy, School of Medicine, Stanford University, Stanford, California
| | - Charles F Lynch
- Department of Epidemiology, University of Iowa, Iowa City, Iowa
| | - Pinki K Prasad
- Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, Louisiana
| | - Rosemary D Cress
- Department of Public Health Sciences, School of Medicine, University of California, Davis, California
| | - Xiao-Cheng Wu
- Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana
| | - Ann S Hamilton
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Helen M Parsons
- Department of Epidemiology and Biostatistics, School of Medicine, The University of Texas Health Science Center, San Antonio, Texas
| | - Gretchen Keel
- Information Management Services Inc, Silver Spring, Maryland
| | - Sarah E Charlesworth
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington
| | - Stephen M Schwartz
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.,Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | | |
Collapse
|
7
|
Prasad PK, Hardy KK, Zhang N, Edelstein K, Srivastava D, Zeltzer L, Stovall M, Seibel NL, Leisenring W, Armstrong GT, Robison LL, Krull K. Psychosocial and Neurocognitive Outcomes in Adult Survivors of Adolescent and Early Young Adult Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2015; 33:2545-52. [PMID: 26150441 DOI: 10.1200/jco.2014.57.7528] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE To characterize psychological and neurocognitive function in long-term cancer survivors diagnosed during adolescence and early young adulthood (AeYA). METHODS Six thousand one hundred ninety-two survivors and 390 siblings in the Childhood Cancer Survivor Study completed the Brief Symptom Inventory-18 and a Neurocognitive Questionnaire. Treatment and demographic predictors were examined, and associations with social attainment (employment, education, and living independently) were evaluated. Logistic regression models were used to compute odds ratios (ORs) and corresponding 95% CIs. RESULTS Among survivors, 2,589 were diagnosed when AeYA (11 to 21 years old). Adjusted for current age and sex, these survivors, compared with siblings, self-reported higher rates of depression (11.7% v 8.0%, respectively; OR, 1.55; 95% CI, 1.04 to 2.30) and anxiety (7.4% v 4.4%, respectively; OR, 2.00; 95% CI, 1.17 to 3.43) and more problems with task efficiency (17.2% v 10.8%, respectively; OR, 1.72; 95% CI, 1.21 to 2.43), emotional regulation (19.1% v 14.1%, respectively; OR, 1.74; 95% CI, 1.26 to 2.40), and memory (25.9% v 19.0%, respectively; OR, 1.44; 95% CI, 1.09 to 1.89). Few differences were noted between survivors diagnosed with leukemia or CNS tumor before 11 years old versus during later adolescence, although those diagnosed with lymphoma or sarcoma during AeYA were at reduced risk for self-reported psychosocial and neurocognitive problems. Unemployment was associated with self-reports of impaired task efficiency (OR, 2.93; 95% CI, 2.28 to 3.77), somatization (OR, 2.29; 95% CI, 1.77 to 2.98), and depression (OR, 1.94; 95% CI, 1.43 to 2.63). CONCLUSION We demonstrated that risk for poor functional outcome is not limited to survivors' diagnoses in early childhood. AeYA is a critical period of development, and cancer during this period can impact neurocognitive and emotional function and disrupt vocational attainment.
Collapse
Affiliation(s)
- Pinki K Prasad
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
| | - Kristina K Hardy
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Nan Zhang
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Kim Edelstein
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Deokumar Srivastava
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Lonnie Zeltzer
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Marilyn Stovall
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Nita L Seibel
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Wendy Leisenring
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Gregory T Armstrong
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Leslie L Robison
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Kevin Krull
- Pinki K. Prasad, Louisiana State University School of Medicine, New Orleans, LA; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Nan Zhang, Deokumar Srivastava, Gregory T. Armstrong, Leslie L. Robison, and Kevin Krull, St Jude Children's Research Hospital, Memphis, TN; Lonnie Zeltzer, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; and Kim Edelstein, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| |
Collapse
|
8
|
Prasad PK. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. Transl Pediatr 2013; 2:53-4. [PMID: 26835287 PMCID: PMC4728923 DOI: 10.3978/j.issn.2224-4336.2013.04.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Affiliation(s)
- Pinki K Prasad
- Division of Pediatric Hematology/Oncology, Louisiana State University Health Sciences Center, Children's Hospital of New Orleans, New Orleans, LA, USA
| |
Collapse
|
9
|
Prasad PK, Signorello LB, Friedman DL, Boice JD, Pukkala E. Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer 2012; 58:421-7. [PMID: 21910209 PMCID: PMC3237747 DOI: 10.1002/pbc.23296] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2010] [Accepted: 07/06/2011] [Indexed: 12/15/2022]
Abstract
BACKGROUND Excess late mortality has been reported among pediatric cancer survivors, but there is a need to further establish risk profiles for non-cancer death and to examine cause-specific mortality among survivors of young adult cancers. PROCEDURES In a nationwide record linkage study in Finland, we identified 9,245 5-year cancer survivors diagnosed before age 35 and treated between 1966 and 1999, and followed them for mortality endpoints from 1971 to 2008. Standardized mortality ratios (SMRs) and 95% confidence intervals (95% CIs) were calculated to compare the observed number of deaths with those expected in the general Finnish population. Primary endpoints included death from cardiovascular and respiratory diseases; death from malignant diseases was excluded. RESULTS Non-malignant disease mortality in the cohort was 90% higher (SMR=1.9, 95% CI: 1.7-2.2) than expected, with SMRs for circulatory and respiratory disease similarly elevated (SMR=1.9, 95% CI: 1.5-2.3 and SMR=2.3, 95% CI: 1.3-3.8, respectively). Important differences were noted amongst patient subgroups, with risk greatest for survivors of central nervous system (CNS) cancer, Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). The SMR's for circulatory disease were 6.6 (95% CI: 4.8-8.9) for HL and 4.8 (95% CI: 2.6-8.1) for NHL for the entire population; but these risks remained elevated for survivors diagnosed between 15 and 34 years of age. CONCLUSIONS Previous studies have shown that there is an elevated risk of non-cancer mortality in childhood cancer survivors; this is one of the first studies that show an increase in cardiovascular and respiratory mortality in long-term survivors of adolescent and young adult cancers.
Collapse
Affiliation(s)
- Pinki K. Prasad
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
,Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Lisa B. Signorello
- Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
,Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
,International Epidemiology Institute, Rockville, MD, USA
| | - Debra L. Friedman
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
,Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - John D. Boice
- Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
,Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
,International Epidemiology Institute, Rockville, MD, USA
| | - Eero Pukkala
- School of Public Health, University of Tampere, Tampere, Finland
,Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
| |
Collapse
|
10
|
Prasad PK, Tandon V, Biswal DK, Goswami LM, Chatterjee A. Use of sequence motifs as barcodes and secondary structures of internal transcribed spacer 2 (ITS2, rDNA) for identification of the Indian liver fluke, Fasciola (Trematoda: Fasciolidae). Bioinformation 2009; 3:314-20. [PMID: 19294000 PMCID: PMC2655052 DOI: 10.6026/97320630003314] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2008] [Revised: 01/16/2009] [Accepted: 02/07/2009] [Indexed: 11/23/2022] Open
Abstract
Most phylogenetic studies using current methods have focused on primary DNA sequence information. However, RNA
secondary structures are particularly useful in systematics because they include characteristics that give
“morphological” information which is not found in the primary sequence. Also DNA sequence motifs from the
internal transcribed spacer (ITS) of the nuclear rRNA repeat are useful for identification of trematodes. The species of liver
flukes of the genus Fasciola (Platyhelminthes: Digenea: Fasciolidae) are obligate parasitic trematodes residing
in the large biliary ducts of herbivorous mammals. While Fasciola hepatica has a cosmopolitan distribution, the
other major species, i.e., F. gigantica is reportedly prevalent in the tropical and subtropical regions of
Africa and Asia. To determine the Fasciola sp. of Assam (India) origin based on rDNA molecular data, ribosomal
ITS2 region was sequenced (EF027103) and analysed. NCBI databases were used for sequence homology analysis and the phylogenetic
trees were constructed based upon the ITS2 using MEGA and a Bayesian analysis of the combined data. The latter approach allowed
us to include both primary sequence and RNA molecular morphometrics and revealed a close relationship with isolates of
F. gigantica from China, Indonesia and Japan, the isolate from China with significant bootstrap values being
the closest. ITS2 sequence motifs allowed an accurate in silico distinction of liver flukes. The data indicate that ITS2 motifs
(≤ 50 bp in size) can be considered promising tool for trematode species identification. Using the novel approach of
molecular morphometrics that is based on ITS2 secondary structure homologies, phylogenetic relationships of the various isolates
of fasciolid species have been discussed.
Collapse
Affiliation(s)
- P K Prasad
- Department of Zoology, North Eastern Hill University, Shillong, Meghalaya, 793022, India
| | | | | | | | | |
Collapse
|
11
|
Prasad PK, Sun CL, Baker KS, Francisco L, Forman S, Bhatia S, Shankar SM. Health care utilization by adult Hispanic long-term survivors of hematopoietic stem cell transplantation: report from the Bone Marrow Transplant Survivor Study. Cancer 2008; 113:2724-33. [PMID: 18831512 DOI: 10.1002/cncr.23917] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Long-term hematopoietic cell transplantation (HCT) survivors have a high prevalence of severe and chronic health conditions, placing significant demands on the healthcare system. The objective of the current study was to evaluate and compare the healthcare utilization by adult Hispanic and non-Hispanic white long-term survivors of HCT. METHODS A mailed questionnaire was used to assess self-reported healthcare utilization in 3 domains: general contact with healthcare system, general physical examination outside cancer center (GPE), and cancer/HCT center visit. Eligible individuals had undergone HCT between 1974 and 1998, at age > or =21 years, and had survived > or =2 years after HCT. RESULTS The cohort included 681 non-Hispanic white and 137 Hispanic survivors. The median age at HCT was 38.3 years, and the median length of follow-up was 6.6 years. Hispanic survivors had lower family income and education and were more likely to lack health insurance. The prevalence of GPE increased significantly over time among non-Hispanic whites (67% at 2-5 years to 76% at 11+ years) but remained unchanged among Hispanics (66% to 61%). Cancer/HCT center visits declined over time among both Hispanics and non-Hispanic whites, but a higher proportion of Hispanics reported cancer/HCT center visits at 11+ years after HCT (81% vs 54%). CONCLUSIONS Compared with non-Hispanic whites, Hispanic survivors are less likely to establish contact with primary care providers years after HCT and to continue to receive care at cancer/HCT centers. Future studies of this population are needed to establish the factors responsible for this pattern of healthcare utilization.
Collapse
Affiliation(s)
- Pinki K Prasad
- Division of Pediatric Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Tandon V, Prasad PK, Chatterjee A, Bhutia PT. Surface fine topography and PCR-based determination of metacercaria of Paragonimus sp. from edible crabs in Arunachal Pradesh, Northeast India. Parasitol Res 2007; 102:21-8. [PMID: 17786478 DOI: 10.1007/s00436-007-0715-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2007] [Accepted: 08/06/2007] [Indexed: 11/25/2022]
Abstract
In several mountainous regions of Northeastern India, foci of Paragonimus infection reportedly involving species that are known to prevail in China have been identified. The present study was undertaken to demonstrate the surface fine topography and sequence analysis of the ribosomal deoxyribonucleic acid (rDNA; second internal transcribed spacer, ITS2) of the metacercarial stages of the lung fluke collected from a mountain stream of the area (Miao, Changlang District in Arunachal Pradesh). The encysted metacercariae were oval in shape and had a smooth surface. The newly excysted metacercaria had a ventral sucker larger than the oral; the body surface was covered with numerous single-pointed and thorn-like tegumentary spines, of which those on the anterior part of the body were bigger in size and showed a gradual reduction in length and number towards the posterior end; dome-shaped papillae in variable numbers were seen around the rim of the oral sucker and were sparsely distributed all over the body surface. The polymerase chain reaction-amplified rDNA ITS2 sequences of the metacercariae were aligned with known sequences for the various species of Paragonimus, and the expectation value was found to be most significant with P. westermani, revealing an absolute match. The surface topography including the number and distribution of papillae and spination patterns and the ITS2 sequences of the metacercariae strongly suggest that the Paragonimus species, prevalent in the region of India, is in fact P. westermani.
Collapse
Affiliation(s)
- V Tandon
- Department of Zoology, North-Eastern Hill University, Shillong, 793022, Meghalaya, India.
| | | | | | | |
Collapse
|
13
|
Prasad PK, Tandon V, Chatterjee A, Bandyopadhyay S. PCR-based determination of internal transcribed spacer (ITS) regions of ribosomal DNA of giant intestinal fluke, Fasciolopsis buski (Lankester, 1857) Looss, 1899. Parasitol Res 2007; 101:1581-7. [PMID: 17712571 DOI: 10.1007/s00436-007-0680-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2007] [Accepted: 07/16/2007] [Indexed: 10/22/2022]
Abstract
Fasciolopsis buski, the zoonotic intestinal flukes of pigs in South and Southeast Asia, is commonly prevalent in regions across Northeast India. Populations of the fluke collected from different parts of the region exhibit variations in morphology. The main objective of our study was to provide molecular characterization of the parasite so as to supplement morphological criteria, using ribosomal DNA cluster (rDNA), which is flanked by more conserved internal transcribed spacer (ITS) regions. We describe herein the ITS sequences of the parasite collected from swine hosts of Assam region. The ITS sequences of both egg and adult origins were found to be identical in length and composition. Phylogenetically, F. buski resembles closely the other members of family Fasciolidae, showing significant expectation value in the alignment. The results corroborate that the ITS sequences are not stage specific and are conserved through different stages of development of the fluke, and thus could be used as species markers.
Collapse
Affiliation(s)
- P K Prasad
- Department of Zoology, North-Eastern Hill University, Shillong, 793022 Meghalaya, India
| | | | | | | |
Collapse
|
14
|
Verma S, Shrivastava R, Prasad PK, Shrivastava VK. Parthenium hysterophorus induced changes in neurotransmitter levels in mouse brain. Phytother Res 2007; 21:183-5. [PMID: 17106867 DOI: 10.1002/ptr.2026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Parthenium hysterophorus (10 mg/0.1 ml/kg body weight) was administered daily to 20 adult male mice and levels of 5-hydroxytryptamine, noradrenaline and dopamine in total brain were quantified on days 31 and 61 after administration. All neurotransmitter levels were decreased significantly, with the effects more prominent in the later part of the experiment. The results suggest that Parthenium hysterophorus interferes in the functioning of the hypothalamo-hypophyseal axis by impairing the biogenic amine levels which may in turn affect the physiology of the peripheral endocrine glands.
Collapse
Affiliation(s)
- Sabita Verma
- Department of Botany, J.M.D.P.L., Mahila College, Madhubani 847211, Bihar, India
| | | | | | | |
Collapse
|